Influenzavirus B Infections - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Pipeline Review, H1 2018, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.
Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 16, 3, 4, 1, 10 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 2, 1 and 1 molecules, respectively.
Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 4
Influenzavirus B Infections - Overview 5
Influenzavirus B Infections - Therapeutics Development 6
Influenzavirus B Infections - Therapeutics Assessment 16
Influenzavirus B Infections - Companies Involved in Therapeutics Development 24
Influenzavirus B Infections - Drug Profiles 38
Influenzavirus B Infections - Dormant Projects 111
Influenzavirus B Infections - Discontinued Products 113
Influenzavirus B Infections - Product Development Milestones 114
Appendix 123
List of Tables
List of Tables
Number of Products under Development for Influenzavirus B Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Influenzavirus B Infections - Pipeline by AbbVie Inc, H1 2018
Influenzavirus B Infections - Pipeline by Adimmune Corp, H1 2018
Influenzavirus B Infections - Pipeline by Altravax Inc, H1 2018
Influenzavirus B Infections - Pipeline by Amarillo Biosciences Inc, H1 2018
Influenzavirus B Infections - Pipeline by Aphios Corp, H1 2018
Influenzavirus B Infections - Pipeline by AusBio Ltd, H1 2018
Influenzavirus B Infections - Pipeline by BioCryst Pharmaceuticals Inc, H1 2018
Influenzavirus B Infections - Pipeline by Biotron Ltd, H1 2018
Influenzavirus B Infections - Pipeline by Cadila Healthcare Ltd, H1 2018
Influenzavirus B Infections - Pipeline by ContraFect Corp, H1 2018
Influenzavirus B Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Influenzavirus B Infections - Pipeline by Emergent BioSolutions Inc, H1 2018
Influenzavirus B Infections - Pipeline by GC Pharma, H1 2018
Influenzavirus B Infections - Pipeline by GlaxoSmithKline Plc, H1 2018
Influenzavirus B Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Influenzavirus B Infections - Pipeline by Johnson & Johnson, H1 2018
Influenzavirus B Infections - Pipeline by Kineta Inc, H1 2018
Influenzavirus B Infections - Pipeline by Medicago Inc, H1 2018
Influenzavirus B Infections - Pipeline by MedImmune LLC, H1 2018
Influenzavirus B Infections - Pipeline by Mucosis BV (Inactive), H1 2018
Influenzavirus B Infections - Pipeline by Novavax Inc, H1 2018
Influenzavirus B Infections - Pipeline by Romark Laboratories LC, H1 2018
Influenzavirus B Infections - Pipeline by Sanofi, H1 2018
Influenzavirus B Infections - Pipeline by Sanofi Pasteur SA, H1 2018
Influenzavirus B Infections - Pipeline by Shionogi & Co Ltd, H1 2018
Influenzavirus B Infections - Pipeline by Sinovac Biotech Ltd, H1 2018
Influenzavirus B Infections - Pipeline by SK Chemicals Co Ltd, H1 2018
Influenzavirus B Infections - Pipeline by Toyama Chemical Co Ltd, H1 2018
Influenzavirus B Infections - Pipeline by TSRL Inc, H1 2018
Influenzavirus B Infections - Pipeline by Vaxart Inc, H1 2018
Influenzavirus B Infections - Dormant Projects, H1 2018
Influenzavirus B Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018
Influenzavirus B Infections - Discontinued Products, H1 2018
List of Figures
List of Figures
Number of Products under Development for Influenzavirus B Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
AbbVie Inc
Adimmune Corp
Altravax Inc
Amarillo Biosciences Inc
Aphios Corp
AusBio Ltd
BioCryst Pharmaceuticals Inc
Biotron Ltd
Cadila Healthcare Ltd
ContraFect Corp
Daiichi Sankyo Co Ltd
Emergent BioSolutions Inc
GC Pharma
GlaxoSmithKline Plc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Kineta Inc
Medicago Inc
MedImmune LLC
Mucosis BV (Inactive)
Novavax Inc
Romark Laboratories LC
Sanofi
Sanofi Pasteur SA
Shionogi & Co Ltd
Sinovac Biotech Ltd
SK Chemicals Co Ltd
Toyama Chemical Co Ltd
TSRL Inc
Vaxart Inc
*If Applicable.